ONKOS SURGICAL® is ecstatic to be partnered with the Musculoskeletal Tumor Society in 2017
July was Sarcoma Awareness Month and we couldn’t think of a better time to honor the esteemed members of the Musculoskeletal Tumor Society (MSTS) and the work they do on a day to day basis. The members of the MSTS and the patients they treat, is quite simply why ONKOS SURGICAL exists. The MSTS released their Summer newsletter to all active members. The ONKOS ad shown ran in their Summer newsletter.
Onkos is also a sponsor at the MSTS Annual Meeting that was held on September 27-29, 2017 in Denver, CO. You can learn more about MSTS by visiting: msts.org.
At this year’s MSTS, ONKOS SURGICAL presented the following Product Theater Sessions:
Thursday, September 28th: PRECISION Oncology from ONKOS SURGICAL; Presenter: Joel Mayerson, MD (Professor of Orthopaedics; Chief, Division of Musculoskeletal Oncology; Director, Orthopaedic Residency Program at The Ohio State University)
Friday, September 29th: Infection Management; Presenter: Nicholas Bernthal, MD (Chief of Musculoskeletal Oncology at UCLA and faculty member at Orthopaedic Institute for Children)
Every tumor is diﬀerent and on occasion, incorporating a biologic in surgery may be necessary. GenVie™ Regenerative Biologics with uDesign™ from ONKOS SURGICAL® allows you to include the biologic of your choice in the pre-op plan, so you know exactly what will be on hand in the OR.
PRECISION Oncology and GenVie with uDesign was presented at the 2017 MSTS in Denver, Colorado.
ELEOSTM Limb Salvage System
Good is not good enough for your patients. ONKOS SURGICAL has a singular commitment to advancing innovation that will dramatically impact the lives of your patients. Introducing ELEOSTM, the modular limb salvage system that is indicated for procedures where radical resection and replacement of the distal femur, proximal femur, proximal tibia or total femur is required. The design combines OPERATIVE SIMPLICITY with a PROVEN DESIGN in one comprehensive,interchangeable system.
Quick-connect, modular trial components accurately replicate the length of the actual ELEOS implants, so that trial reduction is simply performed with greater stability and confidence. ELEOS offers a wide array of both cemented and canal filling stem options to meet surgeon preferences and increase intraoperative flexibility.
When needed, the modularity of the ELEOS system easily allows for intra-operative flexibility offering additional options for stems, tibial augments and compatible acetabular components.
An independent study1 validates the biomechanical stability, reducing instability and implant dislocation.
Inter-component strength is achieved by utilizing a simple to assemble male/female taper implant locking mechanism. If need be, component isassembly is just as simple by utilizing proprietary instrumentation to disengage tapers. Compared to other hinge knee designs that impede normal kinematics in deep flexion, ELEOS features a 5° valgus angle to assist in the restoration of patellofemoral kinematics and a deepened patella groove coupled with a hinge component designed to accommodate relief, reducing patellar subluxation and promoting normal loading patterns.
1. William G. Ward, MD; David Haight, MD; Paul Ritchie, MD; Stan Gordon, BS; Jeffrey J. Eckardt, MD; Dislocation of Rotating Hinge Total Knee Prostheses J Bone Joint Surg Am, 2003 Mar; 85 (3): 448 -453
Dr. Nickolas B. Reimer
ELEOS with uDesignTM from ONKOS SURGICAL: A Surgeon’s Early Experience.
“My practice is varied procedurally, forcing me to solve many diﬀerent clinical issues, intraoperatively.” said Nic Reimer of the Winship Cancer Center at Emory University School of Medicine in Atlanta, GA. “ELEOS™ with uDesign™ allows for extensive modularity, along with the ideal level of simplicity – the system is well thought out. uDesign leverages the simplicity of ELEOS, allowing me to understand exactly what to expect in surgery, well before I walk into the OR. I’m looking forward to future innovation from ONKOS SURGICAL® around the system, taking modular segmental systems further than ever before.”
Nickolas B. Reimer, MD, is a fellowship-trained orthopedic oncologist. His clinical practice focuses on the treatment of bone and soft tissue sarcomas, as well as benign bone and soft tissue tumors, in children and adults. In addition to primary soft tissue and bone tumors, he also treats metastatic disease aﬀecting the musculoskeletal system. Since his practice often requires advanced, unconventional solutions to diﬃcult problems, he also performs complex reconstruction and deformity correction surgery in non-oncologic patients.
GenVieTM Regenerative Biologics
ONKOS SURGICAL was founded to bring focus and innovation to the musculoskeletal oncology. GenVieTM Regenerative Biologics includes a suite of biologic products with applications speciﬁc to musculoskeletal oncology and healing.
CYGNUSTM: Amniotic Tissue Matrix
VIA GRAFTTM: Allogenic Bone Allograft
ALLOGRAFTSTM: Wide range of allografts used for the reconstruction of the muscular system.
ONKOS SURGICAL Partners with PatientIQ to Launch Clinical Registry for Surgical Oncology Patients
PARSIPPANY , N.J., March 14, 2017 /PRNewswire/ — Onkos Surgical, an innovative surgical oncology company, has announced today it has partnered with PatientIQ, a healthcare data, research and analytics technology company, to launch a platform for the collection of clinical data for surgical oncology patients.
“Onkos Surgical has a singular commitment to advancing innovation that will dramatically change the lives of surgical oncology patients. Providing innovation comes with the responsibility of collecting clinical data that will help surgeons track and report on meaningful outcomes measurements,” said Patrick Treacy, Founder and CEO. “The partnership with PatientIQ provides Onkos with a HIPAA compliant, cloud-based application that seamlessly integrates clinical data, patient-reported outcomes and analytics for the various stakeholders in the value chain of patient care. This is another example of how Onkos is committed to investing in the surgical oncology space to drive innovation and change the status quo for surgical oncologists and the patients they care for.”
“The Onkos Registry aims to provide data driven insights with the systematic collection of outcomes data. The platform will create a secure environment for surgeons and patients to collaborate on clinical data points that will lead to advancements in out comes measurement for this challenging patient population,” said Sean Curry, SVP Commercial Operations. The company expects to launch the platform starting in Q2 at select institutions across the country.
PatientIQ is a Chicago based healthcare technology company with a proprietary, HIPAA compliant, cloud-based application that seamlessly integrates clinical data from the EHR, patient-reported outcomes (PROs), and provides analytics for the various stakeholders involved in the healthcare ecosystem.
For more information, visit https://patientiq.io/
ONKOS Named One of the 10 Hottest Medtech Startups of 2017
Onkos Surgical is a specialty medtech company focused on surgical oncology. It has a technology portfolio aimed at utilizing 3D printing capabilities, limb restoration tools, biologic solutions and more to help cancer patients. The suite of technologies is enabled by a service and surgical planning platform called uDesign PATIENT SOLUTIONS.
uDesign is a consultative, concierge level service for surgeons enabling personalized planning for each pa
tient. Additional technologies include the ELEOS Limb Salvage System for procedures where radical resection and replacement of the distal femur, proximal femur, proximal tibia or total femur is required. Every tumor is diﬀerent. Using uDesign, my3D Technology from ONKOS SURGICAL allows the surgeon to utilize a personalized, 3D printed anatomic model that replicates their patients’ anatomy, allowing for better visualization of complex anatomic structures before, during and after surgery.
Highly qualiﬁed image processors segment CT scans to create 3D computer models of the hard and soft (tumor) tissue. The models are then reviewed by the surgeon in partnership with technical experts to generate essential preoperative and intra-operative surgical solutions, allowing the surgeon to better manage individual patient outcomes.
In April, the company announced that it closed a $17.6 million round of Series B funding.
ONKOS SURGICAL® is pleased to announce the appointment of renowned orthopaedic oncologist, Steven Gitelis, MD as Medical Director
Dr. Gitelis will assist the company in expanding upon its core culture of advancing innovation to address clinical challenges in surgical oncology.
Dr. Gitelis is a fellowship-trained orthopaedic surgeon and experienced healthcare administrator. He is Chief of Surgery and Director of the Rush enter for Limb Preservation at the Rush University Medical Center (Chicago, IL). His numerous appointments also include Endowed Chair, Rush Medical College Professor of Orthopedic Oncology and Director, Section of Orthopedic Oncology, Rush-Presbyterian-St. Luke’s Medical Center. Dr. itelis has enjoyed a long-standing relationship with Rush, completing both his orthopaedic surgery residency and general surgery internship at Rush-Presbyterian- St. Luke’s Medical Center. He completed his fellowship at the prestigious Rizzoli Institute (Bologna, Italy) and Mayo Clinic (Rochester, MN).
“ONKOS SURGICAL is proud to have Dr. Gitelis work with us in the capacity of Medical Director,” said Patrick Treacy, Co-founder and CEO of ONKOS. “Building a company requires many talents. Building a medical device company with a singular focus in surgical oncology requires we have a Medical Director who understands the unique needs and challenges of all stakeholders in the healthcare community in which we serve. Dr. Gitelis’ reputation as a leader in the musculoskeletal oncology space is impeccable and we know his experience and expertise will help us shape ONKOS SURGICAL into a very important innovator in this space.”
“I am thrilled to be a part of the ONKOS SURGICAL team as we continue to innovate and commercialize new and exciting treatment modalities in surgical oncology. At the heart of ONKOS SURGICAL is a group of inspiring, enterprising people led by Co-founder and CEO, Patrick Treacy,” said Dr. Gitelis. “ONKOS SURGICAL is committed to developing the next generation of oncological devices and biologics which will enhance the lives of our patients.”
ONKOS SURGICAL Secures $17.6M in Series B Funding Led by Canaan Partners
April 19, 2017, ONKOS SURGICAL, Inc., announced that it closed a $17.6 million round in Series B funding. Canaan Partners led the funding round and existing investors 1315 Capital and 3D Systems also participated. ONKOS will use the new funding to expand its sales, marketing, and R&D platforms to drive aggressive growth and advance the pace of innovation that will dramatically change the lives of surgical oncology patients.
“Every day, musculoskeletal oncologists and their patients are faced with clinical challenges that have been overlooked for too long,” said Patrick Treacy, CEO and Cofounder. “We have the portfolio to deliver meaningful innovation with our advanced 3D printing capabilities, limb restoration technologies, and biologic solutions all enabled with a unique service and surgical planning platform called uDesign™ PATIENT SOLUTIONS. The addition of leading investor Canaan Partners to our roster of investors further validates our opportunity to serve this unique and underserved market,” said Treacy. “The combined intellectual capital and operating experience that Canaan Partners, 1315 Capital and 3D Systems pro vides to our leadership team will enable us to scale our business rapidly and eﬃciently.”
With Canaan’s investment, Stephen Bloch, General Partner at Canaan Partners, joins the ONKOS SURGICAL Board of Directors. “The ONKOS team brings unmatched experience and commitment to serving the challenges and needs of the surgical oncology community,” said Bloch. “Patients and physicians trust Patrick Treacy and his ONKOS colleagues to translate those clinical needs into innovative products that improve patient care.”
Onkos Surgical is committed to help raise awareness of sarcoma and pediatric cancer through fundraising activities, support of cancer research, and partnerships with organizations and regulatory agencies to advocate for change that will impact the lives of cancer patients.
Sarcoma Foundation of America
The mission of the Sarcoma Foundation of America (SFA) is to advocate for sarcoma patients by funding research and by increasing awareness about the disease. The organization raises money to privately fund grants for sarcoma researchers and conducts education and advocacy eﬀorts on behalf of sarcoma patients. To learn more about the Sarcoma Foundation of America please visit www.curesarcoma.org
American Cancer Society
At the American Cancer Society, we’re on a mission to free the world from cancer. Until we do, we’ll be word about prevention. All so you can live longer — and better. To learn more about the American Cancer Society please visit www.cancer.org
For second year in a row, ONKOS SURGICAL participates in Cancer Action Week in New Jersey
For the second year in a row, members of ONKOS SURGICAL had a productive visit with key members of the New Jersey chapter of the ACS Cancer Action Network, including Mary Hess. Also in attendance for the second year was Sen. Joseph Pennacchio from the 26th district of New Jersey.
“Always a pleasure supporting Cancer Action Week and seeing the passion that Mary Hess of the ACS Cancer Action Network brings to the table.” said Gordon Ballad, VP of Operations at ONKOS SURGICAL “A big thank you to Sen. Pennacchio for taking the time to have a thoughtful discussion and looking for appropriate ways for NJ to continue to support cancer research.”
Jan Triani, Senior Director of Regulatory and Quality commented “Surgeons, patients and families deserve a focused company dedicated to surgical oncology. Good enough is simply not good enough for cancer patients and ONKOS SURGICAL is well aligned with the ACS Cancer Action Network of NJ. As always, we were very excited to meet with Sen. Pennacchio to ask New Jersey to continue allocating more money to support cancer research.”
To learn more about the ACS Cancer Action Network, please visit www.acscan.org/states/new-jersey
ONKOS SURGICAL supports Pediatric Oncology at Hackensack Meridian Health
The capstone event for ONKOS Sarcoma Awareness Month was the donation of toys to the boys and girls of the Hackensack Meridian Health Hospital Pediatric Oncology Wing on July 31st. Employee and corporate support for the gifts resulted in over $600 in boxes and boxes of toys. The facility, champion of the Tackle Kids Cancer Foundation, is always in need of toys for their patients as they are cycled through the facility quickly and discarded in order to reduce infection rates in this immune depressed community.
Members of the ONKOS Advocacy Committee were hosted by Amy Glazer, Director of Tackle Kids Cancer and Annual Giving, and Ellen Goldring, Chief of Child Life and Creative Arts Therapy at Hackensack. The group toured the impressive facilities including the out-patient playroom, infusion center, teen game room, in-patient party room, and even the Harry Potter room! The level of in novation, care, and support for the children battling cancer was empowering for the ONKOS team to see first-hand and we look forward to even greater support and partnership in the future.
July was Sarcoma Awareness Month What does Sarcoma Awareness mean to you?
July was Sarcoma Awareness Month. Sarcoma, a type of cancer that occurs in the soft tissue and bones, occurs in 1% of adults with cancer, and 15% of children with cancer. It is among the most life-threatening cancers that children face. That is why ONKOS Surgical is committed to raising awareness of sarcoma and pediatric cancer through partnerships with organizations and regulatory agencies.
The ONKOS Sarcoma Awareness Graphic for the month of July signifies both sarcoma awareness (“yellow”) and hope (“sunflower”).
Throughout the entire month of July, ONKOS SURGICAL employees honored those who have been affected by, and treat sarcoma by answering the question, “What does sarcoma awareness mean to you?”
Senior Director, Portfolio and Patient Solutions
“Although sarcoma is a rare cancer for adults, it is one of the more common pediatric cancers. Early symptoms can be mistaken for growing pains, leading to late diagnoses and limited treatment options. Educating parents on early warning signs of sarcoma could lead to earlier diagnoses, better outcomes, and saving children’s’ lives.”
“In July, when most kids are excited about swimming, summer camps, camping outdoors, picnics, sports, running around with their friends, there are Sarcoma pediatric in-patients who cannot experience any of those activities. They remain in hospital settings in hopes of a successful treatment plan. Bringing awareness is key to helping surgeons help patients with all the tools available to a successful outcome.”
“The most heartbreaking amongst us to receive a cancer diagnosis are the sweet faces of children. For bone and joint cancers, the highest percentage of cases (26.4%) are diagnosed before the patient turns 20 years old. The median age at diagnosis is 23 years younger than overall cancer ages. Raising awareness of sarcoma can help to bring about research and prevention approaches to combat this harrowing disease.”
Steven Gitelis, MD
Orthopaedic Oncologist at Rush University Medical Center (Chicago, IL) Rush Medical College Endowed Professor of Orthopedic Oncology Associate Chief Medical Officer Surgery Past President Medical Staff Medical Director at ONKOS SURGICAL
“While sarcoma is extremely rare this disease can be devastating especially in children. There have been great strides in both treating sarcoma and preserving function. These improvements have been led by a group of specialty centers throughout the United States that are focused on sarcoma. Sarcoma awareness and knowing where to go for treatment or a second opinion is critical for a successful outcome.”
Operations Quality Engineer
“To me, sarcoma awareness means not just informing others about the disease and its impact on the lives of those affected, but also as a way to recruit in an effort to expand the team trying to solve the problem and improve the quality of life of sarcoma patients while doing so.”
A LITTLE ABOUT OUR COMPANY
Patrick Treacy, Antony Koblish and Adele Oliva saw a unique opportunity for one company to demonstrate leadership and set the agenda for innovation in surgical oncology. Founded in 2015, with best-in-class innovation partners, Onkos Surgical will deliver high quality implants and instruments that meet the unique needs of musculoskeletal tumor patients. From modular segmental systems to customized solutions and patient speciﬁc products, Onkos Surgical will partner with surgeons to provide new innovations to help address complex cases. Onkos Surgical has capabilities to increase the speed and delivery of innovation. Onkos Surgical is leveraging new technologies, such as 3D printing, to meet the unique needs of the cancer patient or surgeon. Onkos Surgical will develop products for both hard and soft-tissue applications while continuing to explore strategic partnerships to diﬀerentiate our product portfolio. With great customer responsiveness, manufacturing lead-times and quality, our vision is to be able to service and support the needs of the surgical oncologist.
QUALITY AND COMPLIANCE
Fueled by an organizational culture rooted in integrity, continuous improvement, and perseverance Onkos Surgical will:
- Provide high quality products and services, delivering exceptional, and consistent customer experiences,
- Collaborate with surgeons and regulatory agencies to ﬁnd pathways to provide timely solutions for our customers, and their patients, and
- Uphold the eﬀectiveness of our quality management system through the pursuit of excellence in regulatory, quality, and health care compliance.
To uphold our commitment to delivering the highest standards of compliance rooted in ethics and integrity, Onkos Surgical has established a Compliance Program in accordance with the guidelines published by the Oﬃce of Inspector General and U.S. Department of Health and Human Services. Onkos Surgical is dedicated to complying with the Federal Physician Payment Sunshine Act and have established the compliance program in accordance with the AdvaMed Code of Ethics on Interactions with Health Care Professionals (the “AdvaMed Code”).
It is our expectation that employees, distributors and contractors of Onkos Surgical will comply with our Code of Business Conduct and policies established through our compliance program.